FY2027 EPS Estimates for Omnicell Cut by Zacks Research

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Investment analysts at Zacks Research lowered their FY2027 EPS estimates for shares of Omnicell in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.22 for the year, down from their previous forecast of $1.36. The consensus estimate for Omnicell's current full-year earnings is $1.09 per share.

OMCL has been the topic of a number of other reports. Wells Fargo & Company reduced their price target on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. StockNews.com cut shares of Omnicell from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. JPMorgan Chase & Co. upped their target price on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Benchmark reissued a "buy" rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Finally, Bank of America dropped their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $52.33.

Remove Ads

Omnicell Stock Performance

Omnicell stock traded down $0.34 during mid-day trading on Friday, reaching $37.39. The company's stock had a trading volume of 622,574 shares, compared to its average volume of 492,368. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.75. The business has a 50 day moving average price of $42.26 and a 200-day moving average price of $43.79. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of 138.49, a PEG ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.64% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OMCL. Smartleaf Asset Management LLC lifted its holdings in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the 4th quarter worth approximately $37,000. Van ECK Associates Corp boosted its holdings in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after acquiring an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Omnicell in the fourth quarter valued at approximately $53,000. Finally, First Horizon Advisors Inc. increased its stake in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after acquiring an additional 355 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.